Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialDormandy JA, for the PROactive investigators (St Georges Hosp, London; et al) Lancet 366:1279–1289, 200